BCI Technology Overview - Synchron and Neuralink are leading companies in the Brain Computer Interface (BCI) field, developing brain implants to enable users to control digital devices with their thoughts [1][2][3] - Both companies aim to assist individuals with paralysis by enabling them to control digital devices using their thoughts [12] Device and Technology - Synchron's Stentrode uses a minimally invasive approach, implanting a stent-based device into a blood vessel near the brain's motor cortex with 16 electrodes or channels [3][4][7] - Neuralink's Telepathy involves a more invasive process, directly inserting threads into the brain using a surgical robot, featuring 1,000 electrodes or channels [7][9] - Neuralink aims to triple the number of electrodes next year and implant their first patient with blind sight [7] Implant Process and Risks - Synchron's Stentrode implantation carries the risk of blood clots, managed with medication, with the risk decreasing over time [8] - Neuralink's implantation risks include thread retraction or movement, potentially reducing usable channels [10] Development Stage and Vision - Synchron expects the Stentrode to cost between $50,000 and $100,000, comparable to other implantable medical devices [11] - Neuralink is currently in clinical trials and has received approval to launch trials in Canada, the UK, and the United Arab Emirates [11] - Neuralink envisions expanding access to implants beyond medical needs, aiming for bidirectional communication with the brain and increased bandwidth [12]